세계의 헌팅턴병 치료 시장 : 약제 유형별(승인 의약품, 적응외 의약품), 유통 채널별(병원 약국, 온라인 약국, 소매 약국), 지역별 평가, 기회와 예측(2018-2032년)

Global Huntington's disease treatment market is projected to witness a CAGR of 12.45% during the forecast period 2025-2032, growing from USD 509.56 million in 2024 to USD 1302.78 million in 2032. The market's growth is supported by the rising cases of Huntington's disease, increasing investments towards pharmaceutical products and therapies, rising initiatives to increase awareness about the condition, and rapid advancements in medical research. As per the estimates of UC Davis Health (University of California), Huntington's disease affects about 1 in 10,000 people across the globe. Recent advancements in gene therapies and RNA therapeutics are also supporting the market's expansion.

Additionally, government and nonprofit organizations are fostering collaborations and clinical trial awareness among patients and caregivers. These efforts are not only improving trial participation rates but also accelerating drug development timelines. The market's growth is also driven by the increasing awareness among medical professionals about the ongoing clinical research and advancements in neurodegenerative diagnostics. Increasing investments in disease-modifying therapies coupled with the rising government support for the management of rare diseases is also contributing towards the market's expansion.

Advancements in Early Disease Detection and Treatment Support Market Growth

Early diagnosis and intervention are essential for the management of neurodegenerative disorders such as Huntington's disease. Modern testing techniques aid in the identification of individuals carrying Huntington's disease gene mutation, even before the occurrence of symptoms. This early identification for genetic counseling, clinical monitoring, and enrollment in clinical trials in a time-efficient manner. This in turn is allowing pharmaceutical companies to develop novel drugs, that are able to halt or slow the progression of the disease, providing lucrative growth opportunities for the market. For instance, in February 2025, Latus Bio, Inc. released data in support of its preclinical gene therapy program for Huntington's disease. The company introduced a new computational model for predicting the effects of the knockdown of MSH3 on reducing somatic instability. The company aims to use its AAV-DB-3 capsid variant for delivering an engineered mRNA to reduce the MSH3 in the cells that are affected by Huntington's disease.

Regulatory Approvals Support Market Expansion

Increasing regulatory support and approvals are propelling the market's expansion as they accelerate the adoption and accessibility of new therapeutic solutions. Regulatory bodies such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) are granting regenerative medicine advanced therapy and breakthrough therapy to promising candidates to ensure the availability of advanced therapies and incentivize the leading pharmaceutical companies to invest in Huntington's disease treatments. The provision of such designations facilitates faster drug development and review, ensuring the entry of innovative treatments. For instance, in April 2025, the US FDA granted breakthrough therapy designation to AMT-130 for treating Huntington's disease. Unlike current therapies available in the market, AMT-130 aims to address the underlying genetic cause of the condition and provide long-term solutions for Huntington's. As new drugs and gene therapies progress through clinical stages, the market is expected to expand rapidly, due to improved clinical outcomes and patient access.

Hospital Pharmacies Hold Significant Share of the Market

The segment's dominance is supported by the central role played by hospital pharmacies in the management of complex diseases such as Huntington's disease. A large portion of Huntington's disease medications, including deutetrabenazine and tetrabenazine, often necessitate close medical supervision and are prescription-only. Hospital pharmacies are well-equipped to ensure that both outpatients and inpatients have access to the necessary drugs and are often under the care of multidisciplinary teams such as genetic counselors, neurologists, and psychiatrists. Moreover, hospital pharmacies offer comprehensive services including medication monitoring, management of side effects, and adjustments to treatment regimens, which are crucial for Huntington's disease patients who may experience rapid changes in symptoms.

Meanwhile, leading hospital pharmacies are focusing on expanding their market presence, contributing to the segment's expansion. For instance, in March 2025, Apollo HealthCo Ltd, operator of the online platform Apollo 24/7 and Apollo Pharmacy, announced the expansion of its offline hospital pharmacy network in Bengal, India.

North America Holds a Major Market Share

The region's dominance can be attributed to the strong presence of leading pharmaceutical companies, high investments in research activities, and increasing cases of Huntington's disease in countries such as the United States and Canada. As per the estimates of the Huntington's Disease Society of America, approximately 41,000 Americans have Huntington's, and 200,000 Americans are at risk of inheriting the disease.

The market also benefits from favorable reimbursement policies and high levels of awareness among clinicians and the general population. The US FDA's stance on gene therapies and orphan drugs incentivizes companies to pursue treatments for Huntington's disease. Furthermore, organizations such as Huntington's Disease Society of America and the Hereditary Disease Foundation play a key role in advocacy, funding, and education. Canada, too, is witnessing a rise in Huntington's disease research with several centers of excellence and registry programs promoting real-world data collection. The region also benefits from numerous clinical trials and significant investments in neurodegenerative diseases.

Impact of the U.S. Tariffs on Global Huntington's Disease Treatment Market

The financial strain from the tariffs may divert resources away from research and development activities, forcing companies to scale back on or postpone clinical trials for Huntington's disease therapies due to rising operational costs. This could result in delays in the availability of novel therapeutic solutions and could slow the progress of promising treatments, including gene therapies, which are currently under various stages of development. In response to the tariffs, leading pharmaceutical companies are considering reshoring their manufacturing sites to the United States and diversifying their supply chains. The uncertainties surrounding the trade policies are also deterring investments in Huntington's research, impacting the market's expansion.

Key Players Landscape and Outlook

The key players in the market are actively focusing on developing novel therapeutic solutions that target the root cause of the disease and its progression and provide symptomatic relief. Additionally, the companies are also engaging in mergers and acquisitions to enhance their neurodegenerative pipeline. For instance, in December 2024, H. Lundbeck A/S completed the acquisition of Longboard Pharmaceuticals, Inc., allowing the company to expand its Huntington's portfolio. With Lundbeck's established expertise in neurology and global reach, Longboard's neflamapimod can be efficiently developed, commercialized, and made accessible to a broader patient base. Such acquisitions are expected to support the leading players in the market in expanding their customer base and strengthening their position in the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Huntington's Disease Treatment Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Type
    • 5.2.1.1. Approved Drugs
      • 5.2.1.1.1. Tetrabenazine
      • 5.2.1.1.2. Deutetrabenazine
      • 5.2.1.1.3. Valbenazine
    • 5.2.1.2. Off-Label Drugs
      • 5.2.1.2.1. Antipsychotics
      • 5.2.1.2.2. Antidepressants
  • 5.2.2. By Distribution Channel
    • 5.2.2.1. Hospital Pharmacies
    • 5.2.2.2. Online Pharmacies
    • 5.2.2.3. Retail Pharmacies
  • 5.2.3. By Region
    • 5.2.3.1. North America
    • 5.2.3.2. Europe
    • 5.2.3.3. Asia-Pacific
    • 5.2.3.4. South America
    • 5.2.3.5. Middle East and Africa
  • 5.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Drug Type
  • 5.3.2. By Distribution Channel
  • 5.3.3. By Region

6. North America Huntington's Disease Treatment Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Drug Type
    • 6.2.1.1. Approved Drugs
      • 6.2.1.1.1. Tetrabenazine
      • 6.2.1.1.2. Deutetrabenazine
      • 6.2.1.1.3. Valbenazine
    • 6.2.1.2. Off-Label Drugs
      • 6.2.1.2.1. Antipsychotics
      • 6.2.1.2.2. Antidepressants
  • 6.2.2. By Distribution Channel
    • 6.2.2.1. Hospital Pharmacies
    • 6.2.2.2. Online Pharmacies
    • 6.2.2.3. Retail Pharmacies
  • 6.2.3. By Country Share
    • 6.2.3.1. United States
    • 6.2.3.2. Canada
    • 6.2.3.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Huntington's Disease Treatment Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.1.1. Approved Drugs
        • 6.3.1.2.1.1.1. Tetrabenazine
        • 6.3.1.2.1.1.2. Deutetrabenazine
        • 6.3.1.2.1.1.3. Valbenazine
        • 6.3.1.2.1.2. Off-Label Drugs
        • 6.3.1.2.1.2.1. Antipsychotics
        • 6.3.1.2.1.2.2. Antidepressants
      • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.2.1. Hospital Pharmacies
        • 6.3.1.2.2.2. Online Pharmacies
        • 6.3.1.2.2.3. Retail Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Huntington's Disease Treatment Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Huntington's Disease Treatment Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Huntington's Disease Treatment Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Huntington's Disease Treatment Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Import and Export Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

• 19.1. Clinical Trials
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. H. Lundbeck A/S
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. Bausch Health Companies Inc.
  • 22.3.3. Sun Pharmaceutical Industries Ltd.
  • 22.3.4. Teva Pharmaceuticals Industries Ltd.
  • 22.3.5. Dr. Reddy's Laboratories Ltd.
  • 22.3.6. Pfizer Inc.
  • 22.3.7. Neurocrine Biosciences, Inc.
  • 22.3.8. Hikma Pharmaceuticals PLC
  • 22.3.9. Lupin Limited
  • 22.3.10. Prilenia Therapeutics B.V.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer